EA201492148A1 - Способ лечения немелкоклеточного рака легких - Google Patents
Способ лечения немелкоклеточного рака легкихInfo
- Publication number
- EA201492148A1 EA201492148A1 EA201492148A EA201492148A EA201492148A1 EA 201492148 A1 EA201492148 A1 EA 201492148A1 EA 201492148 A EA201492148 A EA 201492148A EA 201492148 A EA201492148 A EA 201492148A EA 201492148 A1 EA201492148 A1 EA 201492148A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lung cancer
- cell lung
- patient
- inoperable
- nucleotides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649092P | 2012-05-18 | 2012-05-18 | |
| PCT/US2013/041652 WO2013173757A1 (en) | 2012-05-18 | 2013-05-17 | Method for treating non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201492148A1 true EA201492148A1 (ru) | 2015-04-30 |
Family
ID=49581824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201492148A EA201492148A1 (ru) | 2012-05-18 | 2013-05-17 | Способ лечения немелкоклеточного рака легких |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20130310440A1 (enExample) |
| EP (1) | EP2849761A1 (enExample) |
| JP (1) | JP2015522542A (enExample) |
| KR (1) | KR20150024843A (enExample) |
| CN (1) | CN104684564A (enExample) |
| AR (1) | AR091090A1 (enExample) |
| AU (1) | AU2013262589A1 (enExample) |
| BR (1) | BR112014028787A2 (enExample) |
| CA (1) | CA2874092A1 (enExample) |
| EA (1) | EA201492148A1 (enExample) |
| IL (1) | IL235459A0 (enExample) |
| IN (1) | IN2014DN10390A (enExample) |
| PH (1) | PH12014502569A1 (enExample) |
| SG (1) | SG11201407649RA (enExample) |
| TW (1) | TW201402132A (enExample) |
| UY (1) | UY34812A (enExample) |
| WO (1) | WO2013173757A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ513757A (en) | 1999-02-26 | 2004-12-24 | Univ British Columbia | Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| EP4122383B1 (en) | 2010-05-08 | 2025-02-12 | The Regents Of The University Of California | Sem scanner sensing apparatus for early detection of ulcers |
| RU2013145869A (ru) | 2011-03-15 | 2015-04-20 | Дзе Юниверсити Оф Бритиш Коламбиа | КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ |
| CN104473973B (zh) * | 2014-12-19 | 2015-08-05 | 山东创新药物研发有限公司 | 一株戈氏梭菌驯化株的应用 |
| US10182740B2 (en) | 2015-04-24 | 2019-01-22 | Bruin Biometrics, Llc | Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements |
| EP3454866A4 (en) * | 2016-05-13 | 2020-01-08 | Golden Biotechnology Corporation | METHOD AND COMPOSITIONS FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER |
| CA3042103A1 (en) | 2017-02-03 | 2018-08-09 | Bruin Biometrics, Llc | Measurement of susceptibility to diabetic foot ulcers |
| KR102492905B1 (ko) | 2017-02-03 | 2023-01-31 | 브루인 바이오메트릭스, 엘엘씨 | 조직 생존률의 측정 |
| GB2569922B (en) | 2017-02-03 | 2022-02-02 | Bruin Biometrics Llc | Measurement of edema |
| GB2574945A (en) | 2017-11-16 | 2019-12-25 | Bruin Biometrics Llc | Providing a continuity of care across multiple care settings |
| AU2018380431B2 (en) | 2017-12-07 | 2024-10-24 | Bruin Biometrics, Llc | SEM trend analysis |
| WO2019136287A1 (en) * | 2018-01-05 | 2019-07-11 | LifeUnit Inc. | Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria |
| PT3749181T (pt) | 2018-02-09 | 2024-05-15 | Bruin Biometrics Llc | Deteção de lesões nos tecidos |
| AU2019359378B2 (en) | 2018-10-11 | 2025-01-09 | Bruin Biometrics, Llc | Device with disposable element |
| US11642075B2 (en) | 2021-02-03 | 2023-05-09 | Bruin Biometrics, Llc | Methods of treating deep and early-stage pressure induced tissue damage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| CA2728449A1 (en) * | 2008-06-18 | 2009-12-23 | Abbott Laboratories | P/gf-1 companion diagnostic methods and products |
| CA2836676A1 (en) * | 2011-05-19 | 2012-11-22 | Teva Pharmaceutical Industries Ltd. | Method for treating non-small cell lung cancer |
-
2013
- 2013-05-16 UY UY0001034812A patent/UY34812A/es not_active Application Discontinuation
- 2013-05-17 CA CA2874092A patent/CA2874092A1/en not_active Abandoned
- 2013-05-17 SG SG11201407649RA patent/SG11201407649RA/en unknown
- 2013-05-17 AU AU2013262589A patent/AU2013262589A1/en not_active Abandoned
- 2013-05-17 EP EP13791341.4A patent/EP2849761A1/en not_active Withdrawn
- 2013-05-17 CN CN201380030309.9A patent/CN104684564A/zh active Pending
- 2013-05-17 EA EA201492148A patent/EA201492148A1/ru unknown
- 2013-05-17 TW TW102117597A patent/TW201402132A/zh unknown
- 2013-05-17 AR ARP130101729A patent/AR091090A1/es unknown
- 2013-05-17 WO PCT/US2013/041652 patent/WO2013173757A1/en not_active Ceased
- 2013-05-17 US US13/896,737 patent/US20130310440A1/en not_active Abandoned
- 2013-05-17 KR KR20147035652A patent/KR20150024843A/ko not_active Withdrawn
- 2013-05-17 JP JP2015512895A patent/JP2015522542A/ja active Pending
- 2013-05-17 IN IN10390DEN2014 patent/IN2014DN10390A/en unknown
- 2013-05-17 BR BR112014028787A patent/BR112014028787A2/pt not_active IP Right Cessation
-
2014
- 2014-11-02 IL IL235459A patent/IL235459A0/en unknown
- 2014-11-18 PH PH12014502569A patent/PH12014502569A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130310440A1 (en) | 2013-11-21 |
| WO2013173757A1 (en) | 2013-11-21 |
| UY34812A (es) | 2013-12-31 |
| AR091090A1 (es) | 2014-12-30 |
| BR112014028787A2 (pt) | 2017-06-27 |
| IL235459A0 (en) | 2014-12-31 |
| KR20150024843A (ko) | 2015-03-09 |
| CA2874092A1 (en) | 2013-11-21 |
| SG11201407649RA (en) | 2014-12-30 |
| EP2849761A1 (en) | 2015-03-25 |
| TW201402132A (zh) | 2014-01-16 |
| AU2013262589A1 (en) | 2015-01-22 |
| JP2015522542A (ja) | 2015-08-06 |
| PH12014502569A1 (en) | 2015-01-21 |
| IN2014DN10390A (enExample) | 2015-08-14 |
| WO2013173757A8 (en) | 2015-04-30 |
| CN104684564A (zh) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014028787A2 (pt) | método para tratamento de câncer de pulmão de célula não pequena | |
| MX2013013384A (es) | Metodo para tratamiento de cancer de pulmon de celulas no pequeñas. | |
| MX359548B (es) | Agentes de iarn modificados. | |
| AR125906A2 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cáncer | |
| BR112013005872A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| RU2014101547A (ru) | Апоптоз-индуцирующее средство | |
| CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
| BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
| MX2013009191A (es) | Oligonucleotidos antisentido. | |
| RU2019130513A (ru) | Антисмысловые нуклеиновые кислоты | |
| EA201790420A1 (ru) | Средства, представляющие собой модифицированную двухнитевую рнк | |
| BR112015009559A2 (pt) | uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| WO2014022739A3 (en) | Modified rnai agents | |
| PH12014500865A1 (en) | Compounds and methods for enhancing innate immune responses | |
| CY1121037T1 (el) | Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
| EA201171415A1 (ru) | Ингибиторы белков семейства iap | |
| WO2012024396A3 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
| WO2011094335A3 (en) | Microrna signatures predicting responsiveness to anti-her2 therapy | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| WO2015032800A3 (en) | Compositions and methods for inducing senescence in cancer cells | |
| JP2014521342A5 (enExample) | ||
| MX2013010524A (es) | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. | |
| BRPI0612334A2 (pt) | uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncer |